THE PAPAPETROU LAB
The lab is moving to the Mt Sinai Icahn School of Medicine in New York City in April 2014.
Our lab uses somatic cell reprogramming and genetic engineering technologies to develop new models for the study of normal and abnormal hematopoiesis. We are deriving patient-specific induced pluripotent stem cells (iPSCs) and engineering disease-associated genetic and chromosomal abnormalities in normal hPSCs. We are using directed hematopoietic differentiation and functional genetics to better understand the cellular and molecular pathogenesis and the genetic basis of hematologic disorders, particularly myelodysplasia, bone marrow failure and progression to acute leukemia and to identify new therapeutic targets.